HK1216859A1 - Irak抑制劑和其用途 - Google Patents

Irak抑制劑和其用途 Download PDF

Info

Publication number
HK1216859A1
HK1216859A1 HK16104934.3A HK16104934A HK1216859A1 HK 1216859 A1 HK1216859 A1 HK 1216859A1 HK 16104934 A HK16104934 A HK 16104934A HK 1216859 A1 HK1216859 A1 HK 1216859A1
Authority
HK
Hong Kong
Prior art keywords
irak inhibitors
irak
inhibitors
compositions
methods
Prior art date
Application number
HK16104934.3A
Other languages
English (en)
Chinese (zh)
Inventor
Jeremy Robert Greenwood
Geraldine C. Harriman
Rosana Kapeller-Libermann
Craig E. Masse
Shaughnessy Robinson
Donna L. Romero
Mee Shelley
Ronald T. Wester
Original Assignee
Nimbus Iris, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nimbus Iris, Inc. filed Critical Nimbus Iris, Inc.
Publication of HK1216859A1 publication Critical patent/HK1216859A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK16104934.3A 2013-01-10 2014-01-08 Irak抑制劑和其用途 HK1216859A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361751000P 2013-01-10 2013-01-10
US61/751,000 2013-01-10
PCT/US2014/010652 WO2014110114A1 (en) 2013-01-10 2014-01-08 Irak inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
HK1216859A1 true HK1216859A1 (zh) 2016-12-09

Family

ID=51061425

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104934.3A HK1216859A1 (zh) 2013-01-10 2014-01-08 Irak抑制劑和其用途

Country Status (9)

Country Link
US (2) US9175007B2 (enExample)
EP (1) EP2943202A4 (enExample)
JP (1) JP2016505012A (enExample)
CN (1) CN105142639A (enExample)
AU (1) AU2014205577A1 (enExample)
BR (1) BR112015014034A2 (enExample)
CA (1) CA2890911A1 (enExample)
HK (1) HK1216859A1 (enExample)
WO (1) WO2014110114A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ717373A (en) 2010-06-03 2017-11-24 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
HK1216859A1 (zh) * 2013-01-10 2016-12-09 Nimbus Iris, Inc. Irak抑制劑和其用途
CA2925211A1 (en) 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
CN113620958A (zh) 2014-03-19 2021-11-09 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
MX2017001302A (es) * 2014-08-01 2017-10-11 Pharmacyclics Llc Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk.
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP3336090B1 (en) * 2015-08-13 2020-07-22 Beijing Hanmi Pharmaceutical Co., Ltd. Irak4 inhibitor and use thereof
PH12018500554B1 (en) 2015-09-14 2024-01-24 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
WO2019001461A1 (zh) * 2017-06-27 2019-01-03 南京明德新药研发股份有限公司 Irak4抑制剂
CN111032642B (zh) 2017-06-29 2023-07-18 里格尔药品股份有限公司 激酶抑制剂及制造和使用方法
TWI898556B (zh) 2018-07-13 2025-09-21 美商基利科學股份有限公司 吡咯并[1,2-b]嗒衍生物
KR102329235B1 (ko) * 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
SG11202105424PA (en) * 2018-11-30 2021-06-29 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2021016293A1 (en) * 2019-07-22 2021-01-28 University Of Louisville Research Foundation, Inc. Immunomodulatory compositions and methods of using
WO2023075479A1 (ko) * 2021-10-28 2023-05-04 재단법인 대구경북첨단의료산업진흥재단 신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
WO2023183377A1 (en) 2022-03-23 2023-09-28 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1937459A1 (de) 1968-08-02 1970-02-05 Ciba Geigy Neue Pyrimidinderivate und Verfahren zu ihrer Herstellung
US5948911A (en) 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
CA2365578A1 (en) * 1999-03-30 2000-10-12 Seiichi Uchida Thienopyrimidine compounds and salts thereof and process for the preparation of the same
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
JP2005503345A (ja) * 2001-04-30 2005-02-03 バイエル・コーポレーシヨン 新規な４−アミノ−５，６−置換チオフェノ［２，３−ｄ］ピリミジン
WO2003057149A2 (en) 2001-12-28 2003-07-17 Bayer Corporation 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
AU2004227913B2 (en) 2003-03-31 2010-12-02 Trovis Pharmaceuticals, Llc New piperidinylamino-thieno(2,3-d) pyrimidine compounds
WO2005037213A2 (en) 2003-10-14 2005-04-28 Cornell Research Foundation, Inc. Antiinflammatory inhibitors of respiratory burst in adherent neutrophils
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
WO2006010567A1 (de) 2004-07-23 2006-02-02 Curacyte Discovery Gmbh INHIBITOREN DER PHOSPHODIESTERASE 4 UND TNFα-FREISETZUNG
WO2006081072A1 (en) 2005-01-24 2006-08-03 Abbott Laboratories Antagonists of the mglu receptor and uses thereof
EP1899353A1 (en) 2005-06-22 2008-03-19 DeveloGen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
WO2007032854A1 (en) 2005-08-19 2007-03-22 Schering Corporation FUSED TRICYCLIC mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS
MX2008002365A (es) 2005-08-19 2008-03-18 Schering Corp Antagonistas triciclicos fusionados del receptor glutamato metabotropico 1 como agentes terapeuticos.
CA2668997C (en) 2006-11-09 2012-10-09 Ardea Biosciences, Inc. 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20100227853A1 (en) 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
MX2011002263A (es) 2008-09-10 2011-05-23 Kalypsys Inc Aminopirimidinas como inhibidores de receptores de histamina para el tratamiento de enfermedades.
EP2473054B1 (en) 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
WO2011072127A1 (en) 2009-12-10 2011-06-16 The University Of North Carolina At Chapel Hill Selective beta-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents
CA2802641C (en) 2010-07-13 2019-03-12 Nidhi Arora Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
AU2011281015B2 (en) 2010-07-23 2015-09-24 President And Fellows Of Harvard College Tricyclic proteasome activity enhancing compounds
EP3239154A1 (en) 2011-01-10 2017-11-01 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP3048106B1 (en) 2011-11-23 2019-11-06 Cancer Research Technology Limited Thienopyrimidine as inhibitors of atypical protein kinase c
WO2013106535A1 (en) * 2012-01-10 2013-07-18 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2015528801A (ja) 2012-07-11 2015-10-01 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
HK1216859A1 (zh) * 2013-01-10 2016-12-09 Nimbus Iris, Inc. Irak抑制劑和其用途
WO2014194242A2 (en) * 2013-05-31 2014-12-04 Nimbus Iris, Inc. Flt3 inhibitors and uses thereof
WO2014194245A2 (en) * 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof

Also Published As

Publication number Publication date
US20140194417A1 (en) 2014-07-10
US9175007B2 (en) 2015-11-03
US20160068543A1 (en) 2016-03-10
WO2014110114A1 (en) 2014-07-17
CA2890911A1 (en) 2014-07-17
EP2943202A1 (en) 2015-11-18
JP2016505012A (ja) 2016-02-18
BR112015014034A2 (pt) 2017-07-11
CN105142639A (zh) 2015-12-09
EP2943202A4 (en) 2016-08-24
US9751892B2 (en) 2017-09-05
AU2014205577A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
HK1216859A1 (zh) Irak抑制劑和其用途
HK1217410A1 (zh) Erk抑制劑及其用途
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
HK1210696A1 (en) Irak inhibitors and uses thereof
HK1210732A1 (en) Irak inhibitors and uses thereof
EP3665156A4 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES
HK1221660A1 (zh) Acc抑制剂和其用途
HK1221659A1 (zh) Acc抑制剂和其用途
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
WO2014011911A3 (en) Irak inhibitors and uses thereof
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
EP3270694A4 (en) Certain chemical entities, compositions, and methods
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
IL241330B (en) pk - dna suppressor compounds, preparations containing them and their uses
EP3186277A4 (en) Antibodies, compositions, and uses
EP3035936A4 (en) Certain chemical entities, compositions, and methods
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
EP3157515A4 (en) Platinum compounds, compositions, and uses thereof
EP3082819A4 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
WO2014078268A3 (en) Anti-hemagglutinin antibodies and methods of use
WO2015077657A3 (en) Stat3 inhibitors and uses thereof
EP3256450A4 (en) Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
WO2014130741A3 (en) Nme inhibitors and methods of using nme inhibitors
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
AU2015311730A8 (en) CaMKII inhibitors and uses thereof